Technology areas: Biotechnology & Pharmaceuticals • Communications • Medical Devices & Mechanical Engineering
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Institut National De La Sante Et De La Recherche Medicale - I N S E R M is managing 1 pending office action in the Chemistry & Materials technology area. This action involves 1 distinct examiner and a distinct art unit. HYUN, PAUL SANG HWA is the busiest examiner, with 1 pending office action. This single action defines the company's current prosecution status.
The pending office action is situated in the Chemistry & Materials technology area. Because there is a distinct examiner and a distinct art unit involved, the company's current interactions with the USPTO are highly centralized. HYUN, PAUL SANG HWA is the only examiner identified in the data, managing the prosecution. This singular focus means that the outcome of the company's current patenting efforts depends entirely on the review of this individual. Practitioners should prioritize understanding the specific preferences and past decisions of this examiner within the assigned art unit to effectively navigate the process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
| HOLMES, REX R | 1 | 80.1% | +17.9% |
| MATTHEWS, ANDRE L | 1 | 62.3% | +14.5% |
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
| ARIETI, RUTH SOPHIA | 1 | 46.2% | +71.4% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697421 | DEEP BRAIN STIMULATION SYSTEM | HOLMES, REX R | 62d |
| 18030265 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | ARIETI, RUTH SOPHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697421 | DEEP BRAIN STIMULATION SYSTEM | HOLMES, REX R | 62d |
| 18850339 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | BURKETT, DANIEL JOHN | — |
| 18427265 | AUGMENTED REALITY (AR) COLLABORATIVE SYSTEM DESIGNED FOR REMOTE INSTRUCTION OVER LIVE MOBILE VIEWS | MATTHEWS, ANDRE L | — |
| 18579409 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS-MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | NOBLE, MARCIA STEPHENS | — |
| 18030265 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | ARIETI, RUTH SOPHIA | — |
| Art Unit | Apps |
|---|---|
| 3796 | 1 |
| 2621 | 1 |
| 1632 | 1 |
| 1635 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850339 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | BURKETT, DANIEL JOHN | — | §112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18697421 | DEEP BRAIN STIMULATION SYSTEM | HOLMES, REX R | 3796 | §103§112 | Non-Final OA | 62d | Pending | Mar 29, 2024 |
| 18427265 | AUGMENTED REALITY (AR) COLLABORATIVE SYSTEM DESIGNED FOR REMOTE INSTRUCTION OVER LIVE MOBILE VIEWS | MATTHEWS, ANDRE L | 2621 | §103 | Final Rejection | — | Pending | Jan 30, 2024 |
| 18579409 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS-MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Jan 15, 2024 |
| 18030265 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | — | Pending | Apr 04, 2023 |
| 17907324 | NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT | OTTON, ALICIA L | 1699 | §102 | Final Rejection | — | Pending | Oct 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitut National de La Sante Et de La Recherche Medicale has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Daniel John Burkett has the most, with 1 of Institut National de La Sante Et de La Recherche Medicale's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
